loading...| Preferred Name |
Aldesleukin |
|
| Synonyms |
125-L-Serine-2-133-interleukin 2 r-serHuIL-2 Recombinant Human Interleukin-2 Recombinant Human IL-2 Aldesleukin ALDESLEUKIN aldesleukin recombinant human interleukin-2 Proleukin |
|
| Definitions |
A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1498 |
|
| ALT_DEFINITION |
A drug used to treat some types of cancer. It is a form of interleukin-2, a cytokine made by leukocytes (white blood cells), that is made in the laboratory. Aldesleukin increases the activity and growth of white blood cells called T lymphocytes and B lymphocytes. It is a type of biological response modifier. |
|
| CAS_Registry |
110942-02-4 |
|
| code |
C1498 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types. |
|
| Display_Name |
Aldesleukin |
|
| FDA_UNII_Code |
M89N0Q7EQR |
|
| FULL_SYN |
125-L-Serine-2-133-interleukin 2 r-serHuIL-2 Recombinant Human Interleukin-2 Recombinant Human IL-2 Aldesleukin ALDESLEUKIN aldesleukin recombinant human interleukin-2 Proleukin |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Aldesleukin |
|
| Legacy Concept Name |
Aldesleukin |
|
| Maps_To |
Aldesleukin |
|
| NCI_Drug_Dictionary_ID |
39756 |
|
| PDQ_Closed_Trial_Search_ID |
39756 |
|
| PDQ_Open_Trial_Search_ID |
39756 |
|
| Preferred_Name |
Aldesleukin |
|
| prefixIRI |
Thesaurus:C1498 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0218986 |
|
| subClassOf |